EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Immune Response of OAS1, IRF9, and IFI6 Genes in the Pathogenesis of COVID-19

Malena Gajate-Arenas, Ingrid Fricke-Galindo iD, Omar García-Pérez iD, Angélica Domínguez-de-Barros iD, Gloria Pérez-Rubio iD, Roberto Dorta-Guerra iD, Ivette Buendía-Roldán iD, Leslie Chávez-Galán iD, Jacob Lorenzo-Morales, Ramcés Falfán-Valencia iD, Elizabeth Córdoba-Lanús iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25094632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Malena Gajate-Arenas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna,…. Hauptthemen laut MEDLINE: 2',5'-Oligoadenylate Synthetase, COVID-19, SARS-CoV-2, Interferon-Stimulated Gene Factor 3, gamma Subunit. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigación Biomédica en Red, Cabildo de Tenerife, Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID-19 is characterized by a wide range of clinical manifestations, where aging, underlying diseases, and genetic background are related to worse outcomes. In the present study, the differential expression of seven genes related to immunity, IRF9, CCL5, IFI6, TGFB1, IL1B, OAS1, and TFRC, was analyzed in individuals with COVID-19 diagnoses of different disease severities. Two-step RT-qPCR was performed to determine the relative gene expression in whole-blood samples from 160 individuals. The expression of OAS1 (p < 0.05) and IFI6 (p < 0.05) was higher in moderate hospitalized cases than in severe ones. Increased gene expression of OAS1 (OR = 0.64, CI = 0.52–0.79; p = 0.001), IRF9 (OR = 0.581, CI = 0.43–0.79; p = 0.001), and IFI6 (OR = 0.544, CI = 0.39–0.69; p < 0.001) was associated with a lower risk of requiring IMV. Moreover, TGFB1 (OR = 0.646, CI = 0.50–0.83; p = 0.001), CCL5 (OR = 0.57, CI = 0.39–0.83; p = 0.003), IRF9 (OR = 0.80, CI = 0.653–0.979; p = 0.03), and IFI6 (OR = 0.827, CI = 0.69–0.991; p = 0.039) expression was associated with patient survival. In conclusion, the relevance of OAS1, IRF9, and IFI6 in controlling the viral infection was confirmed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

2',5'-Oligoadenylate SynthetaseCOVID-19SARS-CoV-2Interferon-Stimulated Gene Factor 3, gamma SubunitHumansMaleFemaleMiddle AgedNuclear ProteinsAdultAgedMitochondrial Proteins

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviral genesgene expressionimmune response

Substanzen

2',5'-Oligoadenylate SynthetaseOAS1 protein, humanIFI6 protein, humanInterferon-Stimulated Gene Factor 3, gamma SubunitIRF9 protein, humanNuclear ProteinsMitochondrial Proteins

Autor:innen und Institutionen

  • Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna, Spain.
  • HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.
  • Department of Mathematics, Statistics and Operations Research, Faculty of Sciences, Mathematics Section, Universidad de La Laguna, 38200 San Cristóbal de La Laguna, Spain.
  • Translational Research Laboratory on Aging and Pulmonary Fibrosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.
  • Laboratory of Integrative Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.

ORCID-Profile: Ingrid Fricke-Galindo, Omar García-Pérez, Angélica Domínguez-de-Barros, Gloria Pérez-Rubio, Roberto Dorta-Guerra, Ivette Buendía-Roldán, Leslie Chávez-Galán, Ramcés Falfán-Valencia, Elizabeth Córdoba-Lanús

Förderung

  • Centro de Investigación Biomédica en Red
  • Cabildo de Tenerife
  • Ministry of Health
  • Consorcio Centro de Investigación Biomédica (CIBER) de Enfermedades Infecciosas (CIBERINFEC)
  • Instituto de Salud Carlos III
  • Cabildo Insular de Tenerife 2023–2028
  • Agencia Canaria de Investigación, Innovación y Sociedad de la Información—ACIISI 2024
  • Ministerio de Sanidad, Spain

Zitieren

APA

Gajate-Arenas, M., Fricke-Galindo, I., García-Pérez, O., Domínguez-de-Barros, A., Pérez-Rubio, G., Dorta-Guerra, R., Buendía-Roldán, I., Chávez-Galán, L., Lorenzo-Morales, J., Falfán-Valencia, R., & Córdoba-Lanús, E. (2024). The Immune Response of OAS1, IRF9, and IFI6 Genes in the Pathogenesis of COVID-19. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094632

Vancouver

Gajate-Arenas M, Fricke-Galindo I, García-Pérez O, Domínguez-de-Barros A, Pérez-Rubio G, Dorta-Guerra R, et al. The Immune Response of OAS1, IRF9, and IFI6 Genes in the Pathogenesis of COVID-19. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094632

BibTeX
@article{GajateArenas2024,
  author = {Gajate-Arenas, Malena and Fricke-Galindo, Ingrid and García-Pérez, Omar and Domínguez-de-Barros, Angélica and Pérez-Rubio, Gloria and Dorta-Guerra, Roberto and Buendía-Roldán, Ivette and Chávez-Galán, Leslie and Lorenzo-Morales, Jacob and Falfán-Valencia, Ramcés and Córdoba-Lanús, Elizabeth},
  title = {The Immune Response of OAS1, IRF9, and IFI6 Genes in the Pathogenesis of COVID-19},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25094632}
}
Kostenlos starten →